Company: SHPH
Filing Date: 2025-01-15
Form Type: S-1
Source: 0001493152-25-002253
Chunk: 202

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-15
Form: S-1
Chunk 202
---
 as of December 31, 2023 |     | As Reported |             |   |     | Adjustment |            |   |     | As Restated |             |   |
|:---------------------------------------------------|:----|:------------|------------:|:--|:----|:-----------|-----------:|:--|:----|:------------|------------:|:--|
| Additional paid in capital                         |     |             |  19,543,363 |   |     |            |  9,945,692 |   |     |             |  29,489,055 |   |
| Accumulated deficit                                |     |             | (15,487,612 | ) |     |            | (9,945,692 | ) |     |             | (25,433,304 | ) |

Additionally, the Company has provided Note 11 – Quarterly Financial
Data (unaudited and restated) to present the impact of the above restatements on the unaudited quarterly financial information for the
period ended September 30, 2023.

The Company’s prior and updated accounting for
the errors described above do not have any effect on the Company’s previously reported cash or cash flows.

The following tables summarize the effect of the restatement
on each financial statement line item as of the dates indicated:

| Consolidated Balance Sheet as of December 31, 2022 |     | As Reported |            |   |     | Adjustment |            |      |     | As Restated |             |   |
|:---------------------------------------------------|:----|:------------|-----------:|:--|:----|:-----------|-----------:|-----:|:----|:------------|------------:|:--|
| Additional paid in capital                         |     |             | 16,572,741 |   |     |            |  9,945,692 |   -1 |     |             |  26,518,433 |   |
| Accumulated deficit                                |     |             | (8,894,889 | ) |     |            | (9,945,692 | )(2) |     |             | (18,840,581 | ) |

| (1) | Adjustments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 include corrections for stock compensation errors (increase of $7,843,052);                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
 recognition of Series A Preferred Stock accrued dividends (decrease of $402,064);